Skip to main content
SpringerLink
Log in

NICE requests case for ibrutinib in CLL for CDF review

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • NICE. NICE asks company to put leukaemia drug forward for new Cancer Drugs Fund. Media Release : 1 Jun 2016. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE requests case for ibrutinib in CLL for CDF review. PharmacoEcon Outcomes News 755, 41 (2016). https://doi.org/10.1007/s40274-016-3148-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3148-4

Search

Navigation